Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Randomized, Multicenter, Active Comparator Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Combination of APG777 + APG990 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07027527 is registered in ClinicalTrials.gov with Apogee Therapeutics, Inc. as lead sponsor.

NCT NCT07027527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07027527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Randomized, Multicenter, Active Comparator Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Combination of APG777 + APG990 in Adults With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Apogee Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 4, 2025
Completion date
December 31, 2027
Enrollment
86 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis